FOLH1 and hepatocellular carcinoma: Considering that first-line therapy in unresectable and metastatic HCC is based on a synergic approach of antiangiogenic therapy and immunotherapy (bevacizumab/atezolizumab) [1], PSMA-targeting radiopharmaceuticals might play a role in the prediction and the assessment of treatment response, especially in cases where conventional imaging is doubtful.